Angimmune

Executive Summary

Angimmune LLC is a clinical-stage biotechnology company developing Resimmune®, a high-potency anti-CD3 immunotoxin for targeted T-cell depletion. The lead program targets Cutaneous T-Cell Lymphoma (CTCL), with additional potential in autoimmune diseases, immuno-oncology combinations, and organ transplantation. The company leverages a proprietary diphtheria toxin-based platform. Founded in 2007 and based in Rockville, Maryland, Angimmune is privately held and currently in pre-clinical/early clinical stages. Despite limited public information, the platform's unique mechanism—selective depletion of pathogenic T-cells—offers a differentiated approach in oncology and autoimmune spaces.

Upcoming Catalysts (preview)

• Q2 2027Phase 1/2 clinical trial results for Resimmune in CTCL20% success
• Q4 2026IND filing for autoimmune indication (e.g., type 1 diabetes)15% success
• TBDPartnership or licensing deal for platform technology10% success